Management of Hypertension and Advancement in Diagnostic Technologies

Hypertension is one of the major health issues that highlights the shortcomings of the global health system. Every year, on May 17th, World Hypertension Day is observed. It is one of the many initiatives aimed at raising international awareness of hypertension. The asymptomatic nature of hypertension is one of the central challenges. In addition to the strain it places on global healthcare, hypertension is also one of the main modifiable risk factors for ischemic heart disease, stroke, kidney failure, and even premature death. Though it is easy to diagnose, it goes undetected, underestimated, and poorly managed until serious complications arise. 

Global and Regional Scale

As indicated by the WHO, up to 1.4 billion people between the ages of 30 and 79 years were hypertensive in 2024, which accounts for almost 33% of this age group. Two-thirds live in low- and middle-income countries, and only around 1 in 5 (23%) have their condition under control.

Fig. 1: Global trends in the number of adults aged 30–79 years, with hypertension, 1990–2024

India carries a significant share of this burden. Approximately 220 million people suffer from hypertension, one of the leading causes of the country's non-communicable disease burden. To improve the rates of identification, treatment, and management in primary care settings, the Indian Council of Medical Research (ICMR) has been working through the India Hypertension Control Initiative (IHCI). Take a look at the hypertension care cascade; it tells a thought-provoking story as depicted in Fig. 2: of all hypertensive individuals in India.

Fig. 2: Hypertension: gap in prevalence, awareness, treatment, and control of hypertension. (Sources)

Hypertension: Mechanism behind the Invisible Intruder

The RAAS (Renin-Angiotensin-Aldosterone System) 

To understand why blood pressure spikes and how heart medications actually work, one has to look at a system called RAAS. In simple words, it is your body's key mechanism for regulating blood pressure and fluid balance. The heart goes into hyperactivity to circulate blood when your arteries clog, or the human system accumulates too much water. Over time, strain is experienced in the cardiovascular system. 

Under normal conditions, RAAS acts like a smart thermostat. Say your pressure dips; the renal system instantly notices and secretes renin, an enzyme, into the body. Renin detects and turns angiotensinogen, which is discharged by the liver, into angiotensin I. Following this, it is then transformed into angiotensin II by the pulmonary enzyme (ACE).

At this stage, things get more complicated. Angiotensin II immediately narrows your blood vessels, elevating blood pressure.  It also stimulates the production of aldosterone, which signals the kidneys to store water and sodium in order to raise the blood volume and pressure. The mechanism switches off once everything is balanced. But with chronic high blood pressure? That switch gets jammed.

Instead of resetting, your RAAS stays overactive. Daily, the human body continues to clamp down on arteries and gather fluid. This continuous process eventually causes inflammation, damages your blood vessels, and physically alters your heart muscles.  It’s a vicious cycle that damages organs. The target of hypertension drugs like aldosterone blockers, ARBs, and ACE inhibitors is to interrupt that hyperactive loop. 

Fig. 3: Renin-Angiotensin System (Source)

Decoding the Mosaic Theory of Hypertension 

Hypertension does not arise from a single biological pathway; it results from the complex interaction of multiple biological systems. Damage to the blood artery lining (endothelial dysfunction) and modifications to the vessel's structure (vascular remodeling) are both significant contributors. The relaxation of blood vessels is limited by oxidative stress, elevated endothelin-1 (a potent vasoconstrictor), and decreased nitric oxide. This triggers the smaller resistance arteries to thicken up and become stiffer over time. 

The heart rate, the cardiovascular output, and vasoconstriction can all be further elevated by increased sympathetic nervous system activity, especially in obesity-related and neurogenic hypertension. Chronic low-grade inflammation and immunological activation also play a major role. This happens as immune cells like T cells and macrophages enter blood arteries and kidneys, generating pro-inflammatory cytokines like IL-6 and TNF-α to promote oxidative stress and sodium retention. Defects in tubular sodium reabsorption, microvascular rarefaction (loss of capillaries) within the kidneys, and irregularities in the pressure-natriuresis or diuresis association are among the renal mechanisms that contribute to persistent high blood pressure. 

High blood pressure is closely related to metabolic disorders. For those who have metabolic syndrome, this is especially true. One of the main characteristics of metabolic syndrome has always been insulin resistance. Under these circumstances, insulin's capacity to cause blood vessel dilatation and renal elimination of sodium is disrupted; this leads to an increase in blood volume and pressure. Adipose tissue dysfunction triggers dysregulation of adipokines. High amounts of leptin enable the sympathetic nervous system to become more active and the kidneys to retain more sodium. The level of adiponectin, which has protective vasodilatory and anti-inflammatory characteristics, also drops. These changes, together with dyslipidemia (high triglycerides and low HDL), lead to endothelial dysfunction, oxidative stress, and persistent low-grade inflammation. 

These metabolic irregularities improve the probability and extent of hypertension in people with metabolic syndrome by accelerating vascular stiffness, sodium retention, and sympathetic overactivity. 

By highlighting the applicability of DNA methylation, histone modification, non-coding RNAs, and systems determined by genomes, transcriptomics, proteomics, and metabolomics, growing epigenetic and multi-omics research has enhanced our understanding of hypertension in recent years. (Sources) The "mosaic theory" of hypertension, which indicates that multiple pathways continually engage to maintain high blood pressure and contribute to long-term damage to the kidneys, brain, and heart, is an effect of many interconnected systems. (Sources)

Fig. 4: Mosaic Theory of Hypertension (Source)

Clinical Threshold and Common Medicines

Fig. 5: Clinical thresholds, common medicines, and their targets (Source)

Devices and their mechanism

The initial assessment of hypertension usually involves taking a blood pressure reading, whether at a clinic, at home with an electronic device, or by means of 24-hour ambulatory blood pressure monitoring (ABPM). For the purpose of determining kidney health, blood glucose levels, lipid profile, thyroid status, and indicators for target organ damage induced by elevated blood pressure, blood and urine tests are frequently performed together with blood pressure. 

Cuff-based devices, the familiar inflatable sleeve worn around the upper arm or wrist, operate on the oscillometric principle. The cuff identifies even slight vibrations in the artery wall due to blood flow through the compressed channel as it inflates and then gradually deflates. These vibration signals are processed by the instrument into systolic and diastolic parameters. While it is a proven technique, it provides blood pressure readings only at specific points in time and requires the patient to remain still during measurement.

Photoplethysmography (PPG) devices function using a different principle. Light penetrates into the skin from an LED, and the amount of light that is reflected or transmitted is measured by a photodetector. The oscillating optical signal tracks the pulse waveform because blood absorbs light at different intensities depending on the volume of blood circulating through the capillaries at a given time. In transmission mode, commonly used in pulse oximeters, light passes through a fingertip and is detected on the opposite side. In reflection mode, used in most smartwatches and fitness bands, both the emitter and detector are positioned on the same surface, and the reflected signal is measured. When PPG data is combined with machine-learning algorithms trained on large blood pressure datasets, these sensors can estimate blood pressure continuously, without a cuff, across a full day of normal activity.

Fig. 6: Cuff-based and cuffless devices

Breakthrough in Hypertension Diagnosis and Management

The Rise of Artificial Intelligence

Artificial intelligence (AI) has greatly enhanced the identification, treatment, and management of hypertension over the past two years. In their easiest form, ML (Machine Learning) algorithms can forecast blood pressure through analysis of waveform data collected by wearable devices and ECG recordings. They can also find patterns that would take a doctor examining regular readings considerably longer to determine. These innovations are being utilized at a more sophisticated level for predictive simulation of blood pressure trajectory changes, automated treatment monitoring, and clinical decision support.

The example of the company Aktiia is worth noting. They recently acquired CE mark approval on their science-backed, validated application, which was anticipated to be available to consumers in 2025. It offers blood pressure and heart rate data in under 90 seconds by analyzing optical signals collected by placing a fingertip over a smartphone camera. It is powered by a generative AI model that has been trained on 11 billion blood pressure data points collected through their previous wearable devices. No cuff, no dedicated hardware. Just a phone and an AI that has processed more blood pressure data than most clinical studies have ever collected.

By incorporating sensors into chest patches that constantly track several hemodynamic parameters and communicate real-time data to cloud-based algorithms that can alert care teams of significant changes, BioBeat has chosen a different strategy. Certain medical and healthcare facilities are currently using these systems.

The main focus of AI applications in the area of hypertension care is to address frequently reported pitfalls: adherence issues, therapeutic inertia (blood pressure still staying above target levels as there are no changes in the prescribed medication), and the challenge of adapting standard care for a variety of patient groups with varying disorders, genetics, and lifestyle habits. Digital twin simulations, AI-guided titration platforms, and risk-stratification models are all being developed with these specific gaps in mind.

Drug Development

In Addition, the drug pipeline is moving forward, especially for those diagnosed with resistant hypertension, which is defined as blood pressure that remains high irrespective of undergoing treatment with three or more drugs. For many years, there were only limited options readily available to this clinically pertinent group.

Baxdrostat and lorundrostat are aldosterone synthase inhibitors that block the production of aldosterone more selectively than conventional aldosterone blockers, with a potentially better side-effect profile. Aprocitentan targets the endothelin pathway, a vasoconstriction mechanism distinct from the RAAS, offering an alternative therapeutic strategy for patients whose blood pressure isn’t responding to existing drug combinations. Zilebesiran, an RNA interference therapy, has an even better approach. It suppresses angiotensinogen production in the liver at the source, warranting only a handful of injections per year to sustain blood pressure reduction. These are not mere incremental modifications to existing drugs. They represent mechanistically distinct approaches to a problem that has proven resistant to the current pharmacological treatments.

Evolution of Hypertension Research

The implementation of Polygenic Risk Scores (PRS) into clinical practice has significant consequences for the diagnosis of hypertension. A PRS evaluates hundreds or thousands of genetic variants across a genome to assess an individual's hereditary risk of developing hypertension, in comparison to single-gene tests. Clinicians could possibly be able to spot patients at high risk years before blood pressure ever hits a clinical threshold due to these scores, which have begun to show up in standard risk assessment panels. This would alter the focus of intervention from responsive treatment to early, stratified prevention.

Researchers are also advancing the knowledge of the specific biological mechanisms behind various subtypes and symptoms of hypertension by integrating multi-omics techniques, genomics, proteomics, and metabolomics with AI-powered predictive modeling techniques. Novel biomarkers are being developed. There are efforts ongoing to develop non-invasive methods for distinguishing between renovascular causes and primary and secondary hypertension. Long-term developments may include wearable-integrated biosensors, PRS panels based on saliva or blood, and AI-powered digital biomarker platforms that can provide precise, tailored hypertension evaluation at scale in clinical settings and, eventually, beyond them.

The Way Forward:

Hypertension needs an urgent transformation in the digital, data/AI, biotech, and population health sectors to tackle the existing stagnations in control rates and drug development.

The first step includes the broad application of cuffless, continuous blood pressure monitoring through wearables, smartphone apps, and patches (using photoplethysmography, pulse transit time, or ultrasound), facilitating out-of-office real-time data that is more accurate in predicting outcomes and detecting masked hypertension. 

Moreover, Artificial Intelligence and data science will interpret real-world data (like genomes, lifestyle, environment, and social factors) for the right forecasting of blood pressure spikes and customized treatment suggestions. This can also lead to better adherence to treatment through chatbots and virtual coaching, and also the finding of novel disease patterns and diverse treatment effects.

Some interesting concepts, such as RNA interference (which includes targeting angiotensinogen or PCSK9), gene editing (e.g., using CRISPR-Cas9 for lasting effects), regenerative medicine for end-organ damage, and intervention procedures like renal denervation, are all worthy of attention as they show the possibility of durable therapies that act on the root mechanisms rather than the possibility of daily pills.

All in all, such changes will enhance awareness for control, prevention, and treatment of hypertension-related complications worldwide. 

Fig. 7: 5 key areas of progress requirement for Hypertension Control and Treatment (Source)

Please Note: This blog post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health concerns. References are based on official sources.